Merck's new crown oral drug's first quotation announcement.

　　On January 10, the Tianjin Pharmaceutical Purchasing Center released the "New Crown Therapeutic Drug Monogravir Capsules First Quotation Publicity". Excluding tax) between 1100 yuan and 1200 yuan, the main country price is 712 US dollars (about 4826 yuan), and the publicity time is from January 10 to January 16, 2023.

　　According to the announcement, the Office of the National Medical Security Administration recently issued the "Guidelines for the Formation of New Coronary Drugs Price Formation (Trial)", and the innovative therapeutic drugs against the new crown virus approved for marketing from January 1, 2023 will be accepted in a centralized manner for initial quotation.

Hangzhou Merck Pharmaceutical Co., Ltd. took the initiative to refer to the relevant requirements, and submitted the initial quotation and relevant materials for the monogravir capsules that were previously conditionally approved for marketing.

　　It is worth noting that Merck has granted Sinopharm the distribution rights and exclusive import rights of Monogravir in China.

Cai Maisong, a member of the Shanghai Municipal People's Political Consultative Conference and vice president of Sinopharm Holdings, said in an exclusive interview with The Paper at the scene of the two sessions in Shanghai: "Optimistically, Merck's new crown oral drug Monogravir is expected to be sold in the domestic market before the Spring Festival."

　　"At present, it is mainly about procedures, and the problems at the operational level can be overcome." Regarding the latest progress of Monoravir's domestic sales, Cai Maisong introduced to The Paper reporters that in the early morning of January 4, the first batch of new crown oral drug Monora Wei has arrived at the warehouse in Shanghai Waigaoqiao Free Trade Zone. "The quantity is hundreds of thousands of boxes. Now the goods are arriving one after another every day, and the follow-up will continue to purchase."

　　Cai Maisong introduced that Merck, as a global company, has many production bases. Drugs imported from different countries need to be filed in China. At present, relevant departments are further linking up, and the company is still waiting for the approval of relevant departments.

　　Cai Maisong further added to the reporter that the company will put Chinese labels on the drugs next, and the labels may arrive within two days. After the labels are finished, according to the manufacturer's instructions, they can cover the whole country.

　　As for which channels will Monogravir be the first to sell in the future, and which regions will it cover?

Cai Maisong said that after entering the market in the future, there is a high probability that it will start selling from large hospitals.

As for whether it will be distributed to the online diagnosis and treatment platform, Cai Maisong said that the follow-up will be subject to the instructions of relevant departments, and then coordinate.

　　On December 29 last year, the State Food and Drug Administration carried out emergency review and approval in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special approval procedures for drugs, and conditionally approved Merck's new coronavirus treatment drug, Monoravir Capsules (trade name: Li Zhuorui/LAGEVRIO) import registration.

　　Monogravir Capsules is an oral small-molecule novel coronavirus treatment drug for the treatment of mild to moderate novel coronavirus infection (COVID-19) in adults with high risk factors for developing severe disease, such as advanced age, obesity or overweight Patients with severe high-risk factors such as chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, and active cancer.

Patients should use the medicine strictly according to the instructions under the guidance of doctors.

　　Merck's Monogravir capsules are the third new crown oral drugs approved in China after Pfizer Paxlovid and Henan Real Bio Azvudine.

　　At present, both Paxlovid and Azvudine have entered community hospitals in some cities and are prescribed by doctors.

The medical insurance price is 1,890 yuan/box for Pfizer (30 capsules in total), and 270 yuan/box for Azvudine.

　　On the evening of January 8, the National Medical Insurance Administration released a message. The person in charge of the Medical Management Department of the National Medical Insurance Administration introduced, "This year, there are a total of Azvudine tablets, Naimatevir tablets/Ritonavir tablets combined packaging, lung-clearing and detoxification The three new crown treatment drugs of granules participated in the negotiation through the procedures of self-declaration, formal review, and expert review. Among them, Azvudine Tablets and Qingfei Paidu Granules were negotiated successfully, but Paxlovid failed due to high quotations from the manufacturer Pfizer Investment Co., Ltd. Success." Although Paxlovid failed to be included in the medical insurance catalog through negotiation, according to relevant requirements, including Paxlovid, Azvudine Tablets, Monogravir Capsules, Sanhanhuashi Granules, etc., medical insurance will temporarily pay until March 2023 March 31.

　　From the point of view of the product use of the new crown drug, according to the tenth edition of the plan, the applicable population of monogravir capsules is adult patients with mild and medium-sized diseases within 5 days of onset and with high risk factors for progression to severe disease.

The dosage is 800 mg, orally once every 12 hours, for 5 consecutive days.

Not recommended for use during pregnancy and lactation.